3 11. (New) The method of claim 10 wherein the locally effective TNF-α lowering amount of bioactive glass particles is administered prophylactically or therapeutically to prevent or treat peritoneal adhesions.

4 12. (New) The method of claim 10 wherein the locally effective TNF-α lowering amount of bioactive glass particles is administered by intraperitoneal injection of a composition comprising the bioactive glass particles, a suitable carrier for intraperitoneal injection, and one or more therapeutic agents.

5 13. (New) The method of claim 12 wherein the one or more therapeutic agents are selected from the group consisting of healing promotion agents, growth factors, anti-inflammatory agents, and anesthetics.

6 20. (New) The method of claim 10 wherein the bioactive glass particles have a size less than about 2 microns.

7 21. (New) The method of claim 12 wherein the locally effective TNF-α lowering amount of bioactive glass particles is administered by inhalation.

8 22. (New) The method of claim 12 wherein the locally effective TNF-α lowering amount of bioactive glass particles is administered by subcutaneous injection.

9 23. (New) The method of claim 22 wherein the locally effective TNF-α lowering amount of bioactive glass particles is mixed with a biocompatible hydrogel.

10 24. (New) The method of claim 22 wherein the locally effective TNF-α lowering amount of bioactive glass particles is administered at a site at which surgery is to be performed.

11 25. (New) The method of claim 24 wherein the locally effective TNF-α lowering amount of bioactive glass particles is mixed with an anesthetic.